Doctors At TRIHMS Save One-Month-Old Girl Suffering From Retinopathy Of Prematurity Plus Disease
Itanagar: Doctors at the Tomo Riba Institute of Health and Medical Sciences (TRIHMS) in Naharlagun, Arunachal Pradesh, successfully treated a one-month-old girl diagnosed with retinopathy of prematurity plus disease, officials announced on Thursday.
According to the PTI report, Chief Minister Pema Khandu congratulated the team of doctors for the first such surgery in the state.
Also Read:Doctors at Tomo Riba Institute of Health and Medical Sciences perform rare heart surgery on 30-year-old patient
"Heartiest congratulations to the dedicated team at TRIHMS for achieving yet another medical milestone! A 1-month-old baby girl with Retinopathy of Prematurity (ROP) Plus Disease was successfully treated with intravitreal anti-VEGF under topical anaesthesia for the first time in Arunachal Pradesh," Khandu posted on X.
"...this groundbreaking procedure highlights their commitment to delivering advanced healthcare to our people. Kudos to the team for their tireless efforts and service!" he said, news agency PTI reported.
Also Read:Tomo Riba Institute of Health and Medical Sciences doctors perform first Coronary Angioplasty PTCA procedure
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!